GFR-话题@MedSci

#GFR#

483篇内容 | 2610人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1534400, encodeId=6f20153440069, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=何勇教授：第三代EGFR TKI奥希替尼的一线使用经验探讨, objectType=article, longId=155682, objectId=41eb155682eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41eb155682eb, replyNumber=0, likeNumber=66, createdTime=2018-12-14, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41eb155682eb, moduleTitle=何勇教授：第三代EGFR TKI奥希替尼的一线使用经验探讨, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41eb155682eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534399, encodeId=42a51534399b9, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=EGFR突变阳性NSCLC一线治疗持久获益，中位治疗时间达27.6个月, objectType=article, longId=154835, objectId=5ec0154835e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ec0154835e1, replyNumber=0, likeNumber=60, createdTime=2018-12-02, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ec0154835e1, moduleTitle=EGFR突变阳性NSCLC一线治疗持久获益，中位治疗时间达27.6个月, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ec0154835e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534398, encodeId=d9ef1534398ff, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JCO：EGFR突变非小细胞肺癌患者接受厄洛替尼辅助治疗可以改善预后, objectType=article, longId=154705, objectId=7bee154e0525, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bee154e0525, replyNumber=0, likeNumber=68, createdTime=2018-12-01, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bee154e0525, moduleTitle=JCO：EGFR突变非小细胞肺癌患者接受厄洛替尼辅助治疗可以改善预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bee154e0525)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534397, encodeId=2be1153439e91, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=EGFR突变的晚期NSCLC 靶向药物如何使用威力很大？, objectType=article, longId=154209, objectId=629715420920, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=629715420920, replyNumber=0, likeNumber=64, createdTime=2018-11-24, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=629715420920, moduleTitle=EGFR突变的晚期NSCLC 靶向药物如何使用威力很大？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=629715420920)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534396, encodeId=b113153439629, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Exp Eye Res：MicroRNA-218-5p通过PI3K / Akt / mTOR信号通路靶向EGFR抑制翼状胬肉上皮细胞的迁移和增殖, objectType=article, longId=150927, objectId=2aa915092e60, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2aa915092e60, replyNumber=0, likeNumber=12, createdTime=2018-10-14, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2aa915092e60, moduleTitle=Exp Eye Res：MicroRNA-218-5p通过PI3K / Akt / mTOR信号通路靶向EGFR抑制翼状胬肉上皮细胞的迁移和增殖, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2aa915092e60)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534395, encodeId=40d11534395a7, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=【2018WCLC】逆转耐药，EGFR TKIs耐药后联用阿帕替尼的临床价值再探索, objectType=article, longId=150184, objectId=a0d515018464, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0d515018464, replyNumber=0, likeNumber=61, createdTime=2018-10-02, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0d515018464, moduleTitle=【2018WCLC】逆转耐药，EGFR TKIs耐药后联用阿帕替尼的临床价值再探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0d515018464)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534394, encodeId=4ea9153439438, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Neuron：PDGFRβ细胞释放CCL2的生理功能, objectType=article, longId=150065, objectId=fc04150065cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc04150065cf, replyNumber=0, likeNumber=72, createdTime=2018-10-01, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc04150065cf, moduleTitle=Neuron：PDGFRβ细胞释放CCL2的生理功能, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc04150065cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534393, encodeId=d5cf15343935c, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=宋勇教授：超越化疗，阿帕替尼联合多西他赛二线治疗EGFR阴性NSCLC疗效初现, objectType=article, longId=150010, objectId=265815001074, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=265815001074, replyNumber=0, likeNumber=78, createdTime=2018-10-01, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=265815001074, moduleTitle=宋勇教授：超越化疗，阿帕替尼联合多西他赛二线治疗EGFR阴性NSCLC疗效初现, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=265815001074)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534392, encodeId=016815343922c, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=美国FDA批准VIZIMPRO用于EGFR突变的转移性非小细胞肺癌的一线治疗, objectType=article, longId=149975, objectId=90091499e58a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90091499e58a, replyNumber=0, likeNumber=72, createdTime=2018-09-30, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90091499e58a, moduleTitle=美国FDA批准VIZIMPRO用于EGFR突变的转移性非小细胞肺癌的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90091499e58a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534391, encodeId=cdb315343914b, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=FDA批准辉瑞EGFR抑制剂达克替尼用于EGFR突变的局部晚期或转移性NSCLC患者的一线治疗, objectType=article, longId=149971, objectId=bdf71499e193, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdf71499e193, replyNumber=0, likeNumber=79, createdTime=2018-09-30, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdf71499e193, moduleTitle=FDA批准辉瑞EGFR抑制剂达克替尼用于EGFR突变的局部晚期或转移性NSCLC患者的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bdf71499e193)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534390, encodeId=00d41534390e2, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Sci Rep：Runx2是成骨细胞祖细胞增殖所必需的，通过调节Fgfr2和Fgfr3诱导细胞增殖, objectType=article, longId=148979, objectId=a5e71489e93b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5e71489e93b, replyNumber=0, likeNumber=44, createdTime=2018-09-18, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5e71489e93b, moduleTitle=Sci Rep：Runx2是成骨细胞祖细胞增殖所必需的，通过调节Fgfr2和Fgfr3诱导细胞增殖, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5e71489e93b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534389, encodeId=3379153438902, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Am J Kidney Dis：大手术后估计的GFR与医院获得性感染, objectType=article, longId=148467, objectId=3b7c14846e64, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b7c14846e64, replyNumber=0, likeNumber=0, createdTime=2018-09-10, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b7c14846e64, moduleTitle=Am J Kidney Dis：大手术后估计的GFR与医院获得性感染, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b7c14846e64)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534388, encodeId=560f15343887b, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JCO：Capmatinib联合Gefitinib治疗EGFR抑制失败的非小细胞肺癌患者, objectType=article, longId=147810, objectId=bbcb14e81092, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bbcb14e81092, replyNumber=0, likeNumber=63, createdTime=2018-09-01, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bbcb14e81092, moduleTitle=JCO：Capmatinib联合Gefitinib治疗EGFR抑制失败的非小细胞肺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bbcb14e81092)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534387, encodeId=6ba2153438e1f, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JCO：晚期非小细胞肺癌患者Osimertinib或EGFR-TKI治疗的中枢神经系统反应, objectType=article, longId=147673, objectId=4a4a14e6733c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a4a14e6733c, replyNumber=0, likeNumber=65, createdTime=2018-08-31, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a4a14e6733c, moduleTitle=JCO：晚期非小细胞肺癌患者Osimertinib或EGFR-TKI治疗的中枢神经系统反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a4a14e6733c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534386, encodeId=21a91534386a5, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=我国第三代EGFR抑制剂马来酸艾维替尼进入优先审评, objectType=article, longId=146338, objectId=04121463381d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04121463381d, replyNumber=0, likeNumber=54, createdTime=2018-08-12, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04121463381d, moduleTitle=我国第三代EGFR抑制剂马来酸艾维替尼进入优先审评, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04121463381d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534385, encodeId=cb42153438569, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Radiology：对EGFR-TKI治疗后耐药的非小细胞肺癌中T790M突变阳性患者胸部CT特征的研究, objectType=article, longId=144828, objectId=bdde144828d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdde144828d7, replyNumber=0, likeNumber=61, createdTime=2018-07-22, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdde144828d7, moduleTitle=Radiology：对EGFR-TKI治疗后耐药的非小细胞肺癌中T790M突变阳性患者胸部CT特征的研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bdde144828d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534384, encodeId=42a71534384b3, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lancet Respir Med：检测血浆循环肿瘤DNA的EGFR突变作为晚期肺腺癌一线吉非替尼治疗的选择标准（BENEFIT）, objectType=article, longId=144460, objectId=12e614446058, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12e614446058, replyNumber=0, likeNumber=74, createdTime=2018-07-16, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12e614446058, moduleTitle=Lancet Respir Med：检测血浆循环肿瘤DNA的EGFR突变作为晚期肺腺癌一线吉非替尼治疗的选择标准（BENEFIT）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12e614446058)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534383, encodeId=15ce1534383b9, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=PLos One：非小细胞肺癌中VEGFC/VEGFR3轴介导TGFβ1诱导的上皮-间质转化, objectType=article, longId=144456, objectId=870f1444563b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=870f1444563b, replyNumber=0, likeNumber=70, createdTime=2018-07-16, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=870f1444563b, moduleTitle=PLos One：非小细胞肺癌中VEGFC/VEGFR3轴介导TGFβ1诱导的上皮-间质转化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=870f1444563b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534382, encodeId=08eb15343820c, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=CLIN CANCER RES：EGFR突变肺癌中与EGFR酶抑制剂耐药有关的基因突变, objectType=article, longId=142575, objectId=5b781425e582, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b781425e582, replyNumber=0, likeNumber=78, createdTime=2018-07-07, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b781425e582, moduleTitle=CLIN CANCER RES：EGFR突变肺癌中与EGFR酶抑制剂耐药有关的基因突变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b781425e582)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534381, encodeId=04ea153438191, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=三代EGFR-TKI艾维替尼提交国内上市申请, objectType=article, longId=141444, objectId=18441414444a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18441414444a, replyNumber=0, likeNumber=57, createdTime=2018-06-25, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18441414444a, moduleTitle=三代EGFR-TKI艾维替尼提交国内上市申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18441414444a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GFR

2020-05-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

何勇教授：第三代EGFR TKI奥希替尼的一线使用经验探讨

2018-12-14

liuyiping (审核中...)

前往app查看评论内容

#GFR#

EGFR突变阳性NSCLC一线治疗持久获益，中位治疗时间达27.6个月

2018-12-02

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JCO：EGFR突变非小细胞肺癌患者接受厄洛替尼辅助治疗可以改善预后

2018-12-01

liuyiping (审核中...)

前往app查看评论内容

#GFR#

EGFR突变的晚期NSCLC 靶向药物如何使用威力很大？

2018-11-24

智者为医08 (审核中...)

前往app查看评论内容

#GFR#

Exp Eye Res：MicroRNA-218-5p通过PI3K / Akt / mTOR信号通路靶向EGFR抑制翼状胬肉上皮细胞的迁移和增殖

2018-10-14

liuyiping (审核中...)

前往app查看评论内容

#GFR#

【2018WCLC】逆转耐药，EGFR TKIs耐药后联用阿帕替尼的临床价值再探索

2018-10-02

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Neuron：PDGFRβ细胞释放CCL2的生理功能

2018-10-01

liuyiping (审核中...)

前往app查看评论内容

#GFR#

宋勇教授：超越化疗，阿帕替尼联合多西他赛二线治疗EGFR阴性NSCLC疗效初现

2018-10-01

liuyiping (审核中...)

前往app查看评论内容

#GFR#

美国FDA批准VIZIMPRO用于EGFR突变的转移性非小细胞肺癌的一线治疗

2018-09-30

liuyiping (审核中...)

前往app查看评论内容

#GFR#

FDA批准辉瑞EGFR抑制剂达克替尼用于EGFR突变的局部晚期或转移性NSCLC患者的一线治疗

2018-09-30

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Sci Rep：Runx2是成骨细胞祖细胞增殖所必需的，通过调节Fgfr2和Fgfr3诱导细胞增殖

2018-09-18

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Am J Kidney Dis：大手术后估计的GFR与医院获得性感染

2018-09-10

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JCO：Capmatinib联合Gefitinib治疗EGFR抑制失败的非小细胞肺癌患者

2018-09-01

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JCO：晚期非小细胞肺癌患者Osimertinib或EGFR-TKI治疗的中枢神经系统反应

2018-08-31

liuyiping (审核中...)

前往app查看评论内容

#GFR#

我国第三代EGFR抑制剂马来酸艾维替尼进入优先审评

2018-08-12

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Radiology：对EGFR-TKI治疗后耐药的非小细胞肺癌中T790M突变阳性患者胸部CT特征的研究

2018-07-22

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lancet Respir Med：检测血浆循环肿瘤DNA的EGFR突变作为晚期肺腺癌一线吉非替尼治疗的选择标准（BENEFIT）

2018-07-16

liuyiping (审核中...)

前往app查看评论内容

#GFR#

PLos One：非小细胞肺癌中VEGFC/VEGFR3轴介导TGFβ1诱导的上皮-间质转化

2018-07-16

liuyiping (审核中...)

前往app查看评论内容

#GFR#

CLIN CANCER RES：EGFR突变肺癌中与EGFR酶抑制剂耐药有关的基因突变

2018-07-07

liuyiping (审核中...)

前往app查看评论内容

#GFR#

三代EGFR-TKI艾维替尼提交国内上市申请

2018-06-25

科室
- - 订阅+
  - 更多科室
工具
服务